• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Real World Effectiveness of Atezolizumab and Bevacizumab: What Lessons Can We Learn?阿替利珠单抗和贝伐单抗的真实世界有效性：我们能学到什么经验教训？
J Clin Exp Hepatol. 2023 Jul-Aug;13(4):553-555. doi: 10.1016/j.jceh.2023.05.009. Epub 2023 May 19.
2
Fatal intratumoral hemorrhage in a patient with hepatocellular carcinoma following successful treatment with atezolizumab/bevacizumab: A case report.阿替利珠单抗/贝伐珠单抗成功治疗后肝细胞癌患者发生致命性肿瘤内出血：一例报告
World J Clin Cases. 2024 Aug 6;12(22):5177-5183. doi: 10.12998/wjcc.v12.i22.5177.
3
Outcomes of hepatocellular carcinoma by etiology with first-line atezolizumab and bevacizumab: a real-world analysis.基于一线阿替利珠单抗和贝伐珠单抗的病因学肝细胞癌的结局：真实世界分析。
J Cancer Res Clin Oncol. 2023 Jun;149(6):2345-2354. doi: 10.1007/s00432-023-04590-9. Epub 2023 Mar 2.
4
Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice.贝伐珠单抗联合阿替利珠单抗治疗不可切除肝细胞癌的真实世界实践：日本患者的早期经验。
Invest New Drugs. 2022 Apr;40(2):392-402. doi: 10.1007/s10637-021-01185-4. Epub 2021 Sep 29.
5
Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study.阿替利珠单抗联合贝伐珠单抗或仑伐替尼治疗肝细胞癌患者的临床结局：一项多中心真实世界研究。
J Cancer Res Clin Oncol. 2023 Aug;149(9):5591-5602. doi: 10.1007/s00432-022-04512-1. Epub 2022 Dec 13.
6
Cost-effectiveness of atezolizumab plus bevacizumab as first-line therapy for metastatic renal cell carcinoma.阿替利珠单抗联合贝伐单抗作为转移性肾细胞癌一线治疗的成本效益
Expert Rev Pharmacoecon Outcomes Res. 2025 Feb;25(2):173-178. doi: 10.1080/14737167.2024.2399246. Epub 2024 Sep 1.
7
Clinical effects and emerging issues of atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma from Japanese real-world practice.阿替利珠单抗联合贝伐单抗治疗晚期肝细胞癌的日本真实世界临床疗效及新出现的问题
Cancer. 2023 Feb 15;129(4):590-599. doi: 10.1002/cncr.34559. Epub 2022 Nov 24.
8
Lenvatinib Versus Atezolizumab Plus Bevacizumab in the First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Meta-Analysis of Real-World Studies.仑伐替尼对比阿替利珠单抗联合贝伐珠单抗一线治疗不可切除肝细胞癌的真实世界研究的荟萃分析。
Target Oncol. 2024 Mar;19(2):203-212. doi: 10.1007/s11523-024-01035-2. Epub 2024 Jan 30.
9
Analysis of Factors Predicting the Real-World Efficacy of Atezolizumab and Bevacizumab in Patients with Advanced Hepatocellular Carcinoma.分析预测阿替利珠单抗和贝伐珠单抗治疗晚期肝细胞癌患者真实世界疗效的因素。
Gut Liver. 2024 Jul 15;18(4):709-718. doi: 10.5009/gnl240085. Epub 2024 Jun 27.
10
Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors.阿替利珠单抗联合贝伐珠单抗治疗接受酪氨酸激酶抑制剂治疗的肝细胞癌患者的潜在可行性。
Dig Liver Dis. 2022 Nov;54(11):1563-1572. doi: 10.1016/j.dld.2022.07.003. Epub 2022 Jul 27.

本文引用的文献

1
Safety and Efficacy of Atezolizumab-Bevacizumab in Real World: The First Indian Experience.阿替利珠单抗联合贝伐单抗在真实世界中的安全性和有效性：印度的首次经验
J Clin Exp Hepatol. 2023 Jul-Aug;13(4):618-623. doi: 10.1016/j.jceh.2023.02.003. Epub 2023 Feb 10.
2
Disease Etiology and Outcomes After Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: Post-Hoc Analysis of IMbrave150.阿替利珠单抗联合贝伐单抗治疗肝细胞癌后的疾病病因及预后：IMbrave150事后分析
Gastroenterology. 2023 Jul;165(1):286-288.e4. doi: 10.1053/j.gastro.2023.02.042. Epub 2023 Mar 7.
3
Influence of Child-Pugh B7 and B8/9 cirrhosis on laparoscopic liver resection for hepatocellular carcinoma: a retrospective cohort study.B7 和 B8/9 型肝硬化Child-Pugh 分级对肝细胞癌腹腔镜肝切除术的影响：一项回顾性队列研究。
Surg Endosc. 2023 Feb;37(2):1316-1333. doi: 10.1007/s00464-022-09677-x. Epub 2022 Oct 6.
4
Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study.临床实践中阿替利珠单抗联合贝伐珠单抗治疗 HCC 的可重现安全性和疗效：AB-real 研究结果。
Eur J Cancer. 2022 Nov;175:204-213. doi: 10.1016/j.ejca.2022.08.024. Epub 2022 Sep 20.
5
Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer.2010 年至 2019 年全球肝癌流行病学变化：NASH 是肝癌增长最快的病因。
Cell Metab. 2022 Jul 5;34(7):969-977.e2. doi: 10.1016/j.cmet.2022.05.003. Epub 2022 Jun 3.
6
Breaking the Child-Pugh Dogma in Hepatocellular Carcinoma.打破肝细胞癌中的Child-Pugh教条
J Clin Oncol. 2022 Jul 1;40(19):2078-2082. doi: 10.1200/JCO.21.02373. Epub 2022 Mar 28.
7
Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis: A real-world study.阿替利珠单抗联合贝伐珠单抗治疗伴有 A 级和 B 级肝硬化的肝细胞癌患者的安全性和耐受性的初步证据：一项真实世界研究。
Hepatology. 2022 Oct;76(4):1000-1012. doi: 10.1002/hep.32468. Epub 2022 Apr 8.
8
Atezolizumab and bevacizumab in patients with advanced hepatocellular carcinoma with impaired liver function and prior systemic therapy: a real-world experience.阿替利珠单抗和贝伐单抗用于肝功能受损且既往接受过全身治疗的晚期肝细胞癌患者：一项真实世界经验
Ther Adv Med Oncol. 2022 Feb 26;14:17588359221080298. doi: 10.1177/17588359221080298. eCollection 2022.
9
Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma.IMbrave150研究的更新疗效和安全性数据：阿替利珠单抗联合贝伐珠单抗对比索拉非尼治疗不可切除肝细胞癌。
J Hepatol. 2022 Apr;76(4):862-873. doi: 10.1016/j.jhep.2021.11.030. Epub 2021 Dec 11.
10
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.BCLC 策略用于预后预测和治疗推荐：2022 年更新版。
J Hepatol. 2022 Mar;76(3):681-693. doi: 10.1016/j.jhep.2021.11.018. Epub 2021 Nov 19.

Real World Effectiveness of Atezolizumab and Bevacizumab: What Lessons Can We Learn?

作者信息

Kalyan Aparna, Singal Amit

机构信息

Division of Hematology and Oncology, Robert H. Lurie Comprehensive Cancer Centre of Northwestern University, USA.

Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.

出版信息

J Clin Exp Hepatol. 2023 Jul-Aug;13(4):553-555. doi: 10.1016/j.jceh.2023.05.009. Epub 2023 May 19.

DOI:10.1016/j.jceh.2023.05.009
PMID:37440937
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10333938/
Abstract
摘要